Newsfeed : Large-Scale HIV Vaccine Trial Shows Some Success

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Newsfeed » September 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 24, 2009

Large-Scale HIV Vaccine Trial Shows Some Success

For the first time, an HIV vaccine trial has produced positive results: A new vaccine tested on more than 16,000 volunteers in Thailand reduces the risk of HIV infection by more than 30 percent, The New York Times reports. The clinical trial—the largest HIV vaccine trial in history—was backed by the National Institute of Allergy and Infectious Diseases (NIAID), the Thai Ministry of Public Health, the United States Army and patent-holders to the two parts of the vaccine, Sanofi-Pasteur and Global Solutions for Infectious Diseases.

According to the article, the vaccine—known as RV 144—is a combination of two genetically engineered vaccines, Alvac-HIV and AIDSVAX, which previously have not worked in humans. The researchers are unsure as to why these vaccines worked so well in tandem.

“I don’t want to use a word like ‘breakthrough,’ but I don’t think there’s any doubt that this is a very important result,” said NIAID director Anthony S. Fauci, MD. “For more than 20 years now, vaccine trials have essentially been failures. Now it’s like we were groping down an unlit path, and a door has been opened. We can start asking s ome very important questions.”

Col. Jerome H. Kim, MD, manager of the Army’s HIV vaccine program, said half of the 16,402 volunteers were given six doses of two vaccines in 2006 and half were given placebos. They were given regular HIV tests for three years. Of those who received placebos, 74 contracted HIV, while only 51 of those who got the vaccines did. Kim said those statistics show the vaccine is 31.2 percent effective.

While Fauci said that officials would never license a vaccine less than 70 or 80 percent effective, he added, “If you have a product that’s even a little bit protective, you want to look at the blood samples and figure out what particular response was effective and direct research from there.”

“This is not the endgame,” Fauci said about the latest findings. “This is the beginning.”

Search: vaccine, Thailand, National Institute of Allergy and Infectious Diseases, NIAID, Fauci, Thai Ministry of Public Health, United States Army, , Sanofi-Pasteur, Global Solutions for Infectious Diseases, RV 144, Alvac-HIV, AIDSVAX,

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (4 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.